TCGA-E2-A1IU-01A-11R-A14D-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 11
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANDROGEN_RESPONSE+0.350
- ESTROGEN_RESPONSE_EARLY+0.340
- PROTEIN_SECRETION+0.320
- OXIDATIVE_PHOSPHORYLATION+0.290
- HEME_METABOLISM+0.280
- PI3K_AKT_MTOR_SIGNALING+0.240
- FATTY_ACID_METABOLISM+0.220
- ADIPOGENESIS+0.210
- WNT_BETA_CATENIN_SIGNALING+0.200
- PEROXISOME+0.190
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.490
- E2F_TARGETS-0.430
- ANGIOGENESIS-0.390
- G2M_CHECKPOINT-0.370
- PANCREAS_BETA_CELLS-0.340
- ALLOGRAFT_REJECTION-0.280
- INFLAMMATORY_RESPONSE-0.270
- CHOLESTEROL_HOMEOSTASIS-0.260
- COAGULATION-0.250
- MYC_TARGETS_V2-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | DRR168550 | — | — | 0.800 |
| 2 | MNG427 | — | — | 0.798 |
| 3 | TCGA-44-6146-01A-11R-A278-07 | — | cohortA1 | 0.790 |
| 4 | SRR6013579 | — | cohortA1 | 0.783 |
| 5 | 9488f59b-105a-4c4b-844e-23498427b51f | — | — | 0.767 |
| 6 | C3L-01889 | — | cohortA2 | 0.765 |
| 7 | TCGA-E2-A15E-06A-11R-A12D-07 | — | B | 0.752 |
| 8 | MNG1024 | — | — | 0.750 |
| 9 | TCGA-50-5932-01A-11R-1755-07 | — | cohortA2 | 0.748 |
| 10 | TCGA-78-7163-01A-12R-2066-07 | — | cohortA1 | 0.744 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANDROGEN_RESPONSE | 0.350 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.340 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.320 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.290 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.280 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.240 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.210 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PEROXISOME | 0.190 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.150 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.130 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.130 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.090 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.070 | Inavolisib | — uncovered |
| APOPTOSIS | 0.060 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.050 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.040 | Idelalisib | — uncovered |